TY - JOUR
T1 - Molecular dynamics analysis of superoxide dismutase 1 mutations suggests decoupling between mechanisms underlying ALS onset and progression
AU - Kalia, Munishikha
AU - Miotto, Mattia
AU - Ness, Deborah
AU - Opie-Martin, Sarah
AU - Spargo, Thomas P.
AU - Di Rienzo, Lorenzo
AU - Biagini, Tommaso
AU - Petrizzelli, Francesco
AU - Al Khleifat, Ahmad
AU - Kabiljo, Renata
AU - Project MinE ALS Sequencing Consortium
AU - SOD1-ALS clinical and genetic data collection group
AU - Topp, Simon
AU - Mayl, Keith
AU - Fogh, Isabella
AU - Mehta, Puja R.
AU - Williams, Kelly L.
AU - Jockel-Balsarotti, Jennifer
AU - Bali, Taha
AU - Self, Wade
AU - Henden, Lyndal
AU - Nicholson, Garth A.
AU - Ticozzi, Nicola
AU - McKenna-Yasek, Diane
AU - Tang, Lu
AU - Shaw, Pamela
AU - Chio, Adriano
AU - Ludolph, Albert
AU - Weishaupt, Jochen H.
AU - Landers, John E.
AU - Glass, Jonathan D.
AU - Mora, Jesus S.
AU - Robberecht, Wim
AU - Van Damme, Philip
AU - McLaughlin, Russell
AU - Hardiman, Orla
AU - van den Berg, Leonard H.
AU - Veldink, Jan H.
AU - Corcia, Phillippe
AU - Stevic, Zorica
AU - Siddique, Nailah
AU - Ratti, Antonia
AU - Silani, Vincenzo
AU - Blair, Ian P.
AU - Fan, Dong-sheng
AU - Esselin, Florence
AU - de la Cruz, Elisa
AU - Camu, William
AU - Basak, A. Nazli
AU - Siddique, Teepu
AU - Miller, Timothy
AU - Brown, Robert H.
AU - Andersen, Peter M.
AU - Shaw, Christopher E.
AU - Mazza, Tommaso
AU - Ruocco, Giancarlo
AU - Milanetti, Edoardo
AU - Dobson, Richard J. B.
AU - Al-Chalabi, Ammar
AU - Iacoangeli, Alfredo
N1 - Copyright 2023 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2023/10/30
Y1 - 2023/10/30
N2 - Mutations in the superoxide dismutase 1 (SOD1) gene are the second most common known cause of ALS. SOD1 variants express high phenotypic variability and over 200 have been reported in people with ALS. It was previously proposed that variants can be broadly classified in two groups, 'wild-type like' (WTL) and 'metal binding region' (MBR) variants, based on their structural location and biophysical properties. MBR variants, but not WTL variants, were associated with a reduction of SOD1 enzymatic activity. In this study we used molecular dynamics and large clinical datasets to characterise the differences in the structural and dynamic behaviour of WTL and MBR variants with respect to the wild-type SOD1, and how such differences influence the ALS clinical phenotype. Our study identified marked structural differences, some of which are observed in both variant groups, while others are group specific. Moreover, collecting clinical data of approximately 500 SOD1 ALS patients carrying variants, we showed that the survival time of patients carrying an MBR variant is generally longer (∼6 years median difference, p < 0.001) with respect to patients with a WTL variant. In conclusion, our study highlighted key differences in the dynamic behaviour between WTL and MBR SOD1 variants, and between variants and wild-type SOD1 at an atomic and molecular level, that could be further investigated to explain the associated phenotypic variability. Our results support the hypothesis of a decoupling between mechanisms of onset and progression of SOD1 ALS, and an involvement of loss-of-function of SOD1 with the disease progression.
AB - Mutations in the superoxide dismutase 1 (SOD1) gene are the second most common known cause of ALS. SOD1 variants express high phenotypic variability and over 200 have been reported in people with ALS. It was previously proposed that variants can be broadly classified in two groups, 'wild-type like' (WTL) and 'metal binding region' (MBR) variants, based on their structural location and biophysical properties. MBR variants, but not WTL variants, were associated with a reduction of SOD1 enzymatic activity. In this study we used molecular dynamics and large clinical datasets to characterise the differences in the structural and dynamic behaviour of WTL and MBR variants with respect to the wild-type SOD1, and how such differences influence the ALS clinical phenotype. Our study identified marked structural differences, some of which are observed in both variant groups, while others are group specific. Moreover, collecting clinical data of approximately 500 SOD1 ALS patients carrying variants, we showed that the survival time of patients carrying an MBR variant is generally longer (∼6 years median difference, p < 0.001) with respect to patients with a WTL variant. In conclusion, our study highlighted key differences in the dynamic behaviour between WTL and MBR SOD1 variants, and between variants and wild-type SOD1 at an atomic and molecular level, that could be further investigated to explain the associated phenotypic variability. Our results support the hypothesis of a decoupling between mechanisms of onset and progression of SOD1 ALS, and an involvement of loss-of-function of SOD1 with the disease progression.
KW - Amyotrophic lateral sclerosis
KW - Diseaseassociated SOD1 mutations
KW - Molecular dynamics (MD) simulations
KW - Performed principal component analysis
KW - Superoxide Dismutase type 1 (SOD1)
KW - Survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85175446336&partnerID=8YFLogxK
U2 - 10.1016/j.csbj.2023.09.016
DO - 10.1016/j.csbj.2023.09.016
M3 - Article
C2 - 37954145
SN - 2001-0370
VL - 21
SP - 5296
EP - 5308
JO - Computational and Structural Biotechnology Journal
JF - Computational and Structural Biotechnology Journal
ER -